Hyperbaric oxygen in multiple sclerosis
Sir, I would like to correct some of the errors in the recent article by Dr Bates (September 1986 JRSM, p 535) and contribute to the discussion.
My article detailing the evidence for subacute fat embolism as the cause of multiple sclerosis! was not published as a 'hypothesis' in the Lancet and has not been 'severely criticised by neuropathologists'. Only one comment was published", It is established that fat embolism is a cause of disseminated cerebral plaques:' and it is unreasonable to suppose that it does not also affect the cord. The existence of a subacute syndrome is being increasingly recognized", I do not know of any pathologist who would support the assertion that the areas offocal demyelination and shadow plaques, seen in patients dying after a delay with acute fat embolism, are the result of Wallerian degeneration.
Emboli cause perivenous demyelination and can also account for single lesion syndromes. It is necessary to draw attention, yet again, to the nonsense of requiring evidence of more than one lesion, disseminated in time and place in the nervous system, for a 'diagnosis' and before trials of therapy are undertaken.
In relation to the recent trials, Dr Bates implies that criticism has been confined to the 'lay press', despite the publication of several detailed letters in the journals involved.
Dr Bates now feels that hyperbaric oxygen has no place in the treatment of patients with multiple sclerosis, despite positive results in both British trials. In the Newcastle trial" in which Dr Bates participated, 16 out of 60 patients improved, compared with 4 out of 57 in the control group. This is Journal of the Royal Society of Medicine Volume 80 April1987 259 highly significant (P<O.01), but the authors limited their tests of significance to individual systems, as, for exam ple, in cerebellar or pyramidal function. This can only be defended if the disabilities in the treated and control patients are carefully matched, because of the variable age of lesions. The patient reports for bowel and bladder function also indicated that there was a significant benefit from oxygen therapy, with 12 out of 51 affected patients improving, compared to 3 out of 47 in the control group. This is also highly significant (P<0.03), but was dismissed as 'subjective'. With no follow-on treatment, it is not surprising that the benefit has not been maintained.
In the more recent study by Wiles et al. 6 , the overall results are not available; only the statistical analyses have been published, but they contain levels of significance. The only numerical data given relate to 20 of the patients with the most severe disturbances of bladder function, who were selected for cystometric studies. Of the 9 patients who received oxygen, 5 showed improvement of bladder capacity and 4 remained stable. In the control group of 11 patients, only one patient improved, but one deteriorated and the remaining 9 patients did not change. The simple test of significance used, by not allowing for the patient in the control group who deteriorated, gave a P value of 0.07. Allowing for this factor, the result becomes significant (P<0.03) at the same level achieved in the Newcastle trial and the successful study by Fischer et al,' Subgroups of patients have also been shown to have benefited in other trials reported as negative. Another detailed study of bladder function using hyperbaric oxygen in multiple sclerosis patients, conducted by urologists, has also reported benefit under double-blind conditions".
As the editorial that accompanied the trial by Fischer et al. stressed, it is essential in therapeutic trials in multiple sclerosis for patients to be matched for age, sex, type of disease and clinical course. By careful attention to this detail, Fischer et al,' demonstrated a clearly beneficial effect from oxygen therapy, the overall difference between the treated and control groups being highly significant (P<O.OOOl). The study has established a benchmark for trials in this disease. In the British trials and several further American studies only the patient groups were matched, not the individual patients.
Of course the results of oxygen therapy in chronic patients, although statistically significant in several trials, are not spectacular, but can dramatic results be expected in patients with typical disease durations of 12 years and average Kurtzke scores of 15-0? Perhaps Dr Bates may care to detail the extent of the sclerosis in the nervous system in these patients and how much of the damage is likely to be reversible? To attempt to dismiss the use of oxygen in the disease process underlying multiple sclerosis, based on trials of chronic patients, is scientifically indefensible and obviously absurd. Sir, Dr Bates' obituary for hyperbaric oxygenation in multiple sclerosis (September 1986 JRSM, p 535) is premature; indeed, evidence is accumulating that it is destined for prolonged life.
-When using a fixed-pressure protocol, it soon becomes obvious that some patients do not respond at 2 atmospheres and may even deteriorate. It is unfortunate that the studies quoted as evidence for the ineffectiveness of hyperbaric oxygen were conducted after Neubauer in 1983 had pleaded, in an open letter to all baromedical physicians, that a low-pressure, variable protocol be used for the initial treatment course in conjunction with regular follow-up exposures.
Dr George Schumacher, a former chairman of the International Federation of Multiple Sclerosis Societies, has stated that 'the only dependable evidence of beneficial therapeutic effect is stabilisation, that is, no further worsening of the clinical status thenceforward ... Longitudinal comparisons over time of each patient's pre-and post-treatment status would provide the essential data", Preliminary results of several long-term studies conducted in hyperbaric units maintained by Action for Research into Multiple Sclerosis (ARMS) have recently been released". In the light of these results (Table 1) , we now advise our members to continue with regular maintenance treatment, whether or not they enjoyed improvement from their initial course of treatment.
The long-term results from many more of our centres, where patients have been titrated against Sir, I remain of the opinion that the perivenous lesions seen in patients suffering cerebral fat emboli are due to local ischaemia and show both loss of myelin and ofaxons, unlike the true perivenous primary demyelination seen in the disease of multiple sclerosis.
With respect to the comments that Dr James makes relating to the Newcastle trial, it is not reasonable simply to sum the improvements noted in individual groups and assume that they relate to different patients. It is not, therefore, correct to say that 16 patients improved in the treated group compared with only 4 in the control group. We also now have evidence that the objective tests of bladder function performed in our patients did not confirm the symptomatic improvement noted in patients in the treatment cohort. In the controlled trials throughout the world, no patient group or subgroup showed a level of improvement in any way similar to that documented by Fischer or claimed in the earlier uncontrolled trials.
Dr James' major criticism relates to the fact that patients who were studied in all of the controlled trials had chronic progressive multiple sclerosis and he rightly points out that this is the group in whom least improvement could be expected. It is nonetheless the group in whom the original small controlled trial and the documented uncontrolled trials claimed to show such a significant benefit. The purpose of the controlled trials was to test the suggestion made by Fischer that patients with chronic progressive multiple sclerosis were helped by hyperbaric oxygenation, and they uniformly failed to show this benefit. During the course of the major controlled trials, the proponents of the therapy suggested several modifications in the method oftreatment and claimed that the trials were being improperly performed, a phenomenon which might be described as moving the goal posts during the course of the game. The suggestions that the treatment now works not in chronic disease as originally claimed but rather in the acute relapsing form of the illness must, by analogy, be regarded as an attempt to move the pitch! It is not presently possible for me to prove that hyperbaric oxygenation does not help in patients with acute remitting and relapsing disease, but by the very nature of their disease we expect to see improvement in these patients and the onus of proofof efficacy surely lies with the proponents of this particular form of therapy.
With respect to the letter from Dr Perrins, I should have thought it obvious that to undertake a form of treatment and then compare the outcome in those patients who elected to continue the treatment with those who decided to abandon it was so obviously a false premise as to require no further comment. I therefore remain of the OpInIOn that hyperbaric oxygenation is not a form of therapy in the disease of multiple sclerosis.
DAVID BATES

Department of Neurology Royal Victoria Infirmary, Newcastle upon Tyne
Primary small bowel ganglioneuroblastoma and 'Friedreich's ataxia' Sir, One of the difficulties in publishing of single case reports is that the possibility of discussion of the diagnosis is limited. I would just like to question the assumption of Barr et al. (October 1986 JRSM, p 612)that the mentally subnormal index case and her mother both had Friedreich's ataxia. Friedreich's ataxia, as we currently know it, is an autosomal recessive disorder and is not associated with mental handicap. Whatever neurological condition the patient had, it is perhaps as important to be as precise about the niceties of the neurological diagnosis as of the histology of the complicating tumour. J B P STEPHENSON
Consultant in Paediatric Neurology
Royal Hospital for Sick Children, Glasgow
*Mr Barr replies below:
Sir, We must refute Dr Stephenson's allegation that we were less concerned with the niceties of neurological diagnosis than with the complicating tumour, Our patient and her mother were diagnosed as having Friedreich's ataxia, not by ourselves but by colleagues. When we were preparing to submit our report, we were concerned as to the accuracy of the diagnosis because of the possible dominant inheritance and the mental retardation. We found that Bell and Carmichael had identified two inheritance patterns, a common autosomal recessive and another dominantI. We also found an authoritative reference that stated that a small percentage of patients are mentally retarded-. In addition, our patient travelled to London to be presented to a distinguished audience at the Royal Society of Medicine. They were able to examine and question her prior to the presentation and the diagnosis was not questioned. We have endeavoured to be as accurate as possible and to confirm our and our colleagues' diagnosis. hyperemesis is indeed frequently associated with significant changes in thyroid hormone levels", Normal pregnancy induces a thyroxine-binding globulin dependent increase in both total T4 and T3 concentration and a decrease in T3 resin uptake, while the free T4 and T3 indices remain in the normal non-pregnant range. In hyperemesis gravidarum, Journal of the Royal Society of Medicine Volume 80 April1987 261 total T4 and T3 resin uptake is frequently elevated above the values observed in healthy pregnant women, resulting in an increased free T4 index in 73% of patients with hyperemesis gravidarum. The thyroid-stimulating hormone response to the injected thyrotrophin-releasing hormone is blunted. Characteristically, total T3 concentrations are within the normal pregnant range.
In contrast, increased total T3 and free T3 index are evident in true hyperthyroidism, in addition to increased T4 concentrations. Moreover, the hyperthyroxinaemia of hyperemesis gravidarum disappears in one to several weeks whether or not antithyroid drugs are used.
Hyperemesis gravidarum thus represents a 'transient hyperthyroxinaemic state' also seen in acute medical illness with malnutrition, acute psychiatric illness and high altitude exposure".
The knowledge of these alterations in thyroid function tests in hyperemesis gravidarum is important for the obstetrician and endocrinologist, since no specific thyroid treatment is required for this transient, isolated hyperthyroxinaemia. 
